JPMorgan Chase & Co.'s Chief Executive Jamie Dimon told analysts on Wednesday he plans to stay in the job "for a few more ...

San Francisco and its hotel industry are partnering to beef up security around this week's 43rd annual J.P. Morgan Healthcare ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

YPF (NYSE:YPF) +0.8% in Friday's trading after earlier rising to a new 52-week high of $47.43, after J.P. Morgan upgrades the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/98.DhP-XEBZ.js ...

Illumina’s Q4 revenue in 2024 was up 1% from the same period in 2023, totalling $1.1bn. Despite the positive end to the year, ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Expected Solana and XRP ETFs could attract sizable investment, JP Morgan analysts said, but it's unlikely they'll match the ...

The research team at J.P. Morgan is out with the firm's 2025 Year Ahead Best Idea list, and we found five companies that look ...

Incyte told JP Morgan attendees of plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GVHD.

The J.P. Morgan Healthcare Conference attracts thousands of attendees each year from the provider, insurance, digital health ...

Erin Whaley, Tammy Ward Woffenden and Paul M. Mahoney Jr. of Troutman Pepper Locke LLP discuss key market and legal ...